Heart failure & cardiomyopathiesSecondary analysis
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial
- Post Hoc Analysis of the SCORED Randomized Controlled Trial
- competing-risk proportional hazards models
Authors' conclusion
Increasing HF stage is associated with a higher risk of HF, major adverse cardiovascular events, and kidney events. Asymptomatic stage B (pre-HF) increased cardiovascular and renal events by >2- and 5-fold, respectively. The benefits of sotagliflozin are consistent, irrespective of HF stage.
Study context
- Population
- Patients with diabetes and kidney disease in the SCORED trial, grouped by 2022 AHA/ACC/HFSA heart failure (HF) stagestage A 741 · stage B (pre-HF) 6,560 · stage C/D (established HF) 3,283
- Comparison
- the association between HF stage and these end points, and the effect of sotagliflozin versus placebo by HF stage
- Stage An = 741
- Stage B (pre-HF)n = 6,560
- Stage C/Dn = 3,283
Primary result
As reported in the abstract
Median NT-proBNP and hs-cTnT by HF stage
- The median NT-proBNP and hs-cTnT increased with HF stage
Further findings
| Outcome | hazard ratio (95% CI) | |
|---|---|---|
| Primary outcome (cardiovascular death and HF-related events), sotagliflozin vs placebo by HF stage · similar irrespective of HF stage | 0.74 (0.63–0.88) | |
| 0.512Hazard ratio (log scale) |
- Primary outcome (cardiovascular death and HF-related events), sotagliflozin vs placebo by HF stage — higher absolute benefit in each HF stage
- P -trend IRR =0.002
- Primary outcome (cardiovascular death and HF-related events), sotagliflozin vs placebo by HF stage: P interaction =1.00
Primary outcome/major adverse cardiovascular events by HF stage (placebo group)
- Increasing HF stage was associated with a 2- to 4-fold increase
Kidney-specific composite by HF stage
- 5-fold higher in stage B (pre-HF) versus stage A but similar in stages B and C/D
Absolute benefit for the kidney-specific end point
- comparable for stages B and C/D
Original publication
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial. Circ Heart Fail. Published 22 January 2026. doi:10.1161/circheartfailure.125.013054
Summarised from the published abstract; every number is checked against it